The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 11, 2013
Filed:
Mar. 26, 2012
Yasutsugu Ueda, Clinton, CT (US);
Timothy P. Connolly, Portland, CT (US);
John F. Kadow, Wallingford, CT (US);
Nicholas A. Meanwell, East Hampton, CT (US);
Tao Wang, Farmington, CT (US);
Chung-pin H. Chen, Madison, CT (US);
Kap-sun Yeung, Madison, CT (US);
Zhongxing Zhang, Madison, CT (US);
David Kenneth Leahy, Hightstown, NJ (US);
Shawn K. Pack, Plainsboro, NJ (US);
Nachimuthu Soundararajan, Kendall Park, NJ (US);
Pierre Sirard, St. Jean sur Richelieu, CA;
Kathia Levesque, Ste-Catherine, CA;
Dominique Thoraval, Candiac, CA;
Yasutsugu Ueda, Clinton, CT (US);
Timothy P. Connolly, Portland, CT (US);
John F. Kadow, Wallingford, CT (US);
Nicholas A. Meanwell, East Hampton, CT (US);
Tao Wang, Farmington, CT (US);
Chung-Pin H. Chen, Madison, CT (US);
Kap-Sun Yeung, Madison, CT (US);
Zhongxing Zhang, Madison, CT (US);
David Kenneth Leahy, Hightstown, NJ (US);
Shawn K. Pack, Plainsboro, NJ (US);
Nachimuthu Soundararajan, Kendall Park, NJ (US);
Pierre Sirard, St. Jean sur Richelieu, CA;
Kathia Levesque, Ste-Catherine, CA;
Dominique Thoraval, Candiac, CA;
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:X is C or N with the proviso that when X is N, Rdoes not exist;W is C or N with the proviso that when W is N, Rdoes not exist;V is C;E is hydrogen or a pharmaceutically acceptable salt thereof; andY is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:L and M are independently selected from the group consisting of C-Calkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.